↓ Skip to main content
Altmetric
What is this page?
Embed badge
Share
Share on Twitter
Share on Facebook
Share by email
The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma
Overview of attention for article published in Journal of Gastroenterology, August 2010
Altmetric Badge
About this Attention Score
Average Attention Score compared to outputs of the same age and source
Mentioned by
patent
1
patent
Citations
dimensions_citation
14
Dimensions
Readers on
mendeley
25
Mendeley
connotea
2
Connotea
Summary
Patents
Dimensions citations
So far, Altmetric has seen
1
patent that references this research output.
BODY CAVITY EFFUSION SUPPRESSANT
Application EP-2821079-A4
European Patent Office
04 May 2016